DE60107074T2 - Kristallin form ii von cabergolin - Google Patents

Kristallin form ii von cabergolin Download PDF

Info

Publication number
DE60107074T2
DE60107074T2 DE60107074T DE60107074T DE60107074T2 DE 60107074 T2 DE60107074 T2 DE 60107074T2 DE 60107074 T DE60107074 T DE 60107074T DE 60107074 T DE60107074 T DE 60107074T DE 60107074 T2 DE60107074 T2 DE 60107074T2
Authority
DE
Germany
Prior art keywords
cabergoline
crystal form
mixture
solvent
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60107074T
Other languages
German (de)
English (en)
Other versions
DE60107074D1 (de
Inventor
Attilio Tomasi
Stefania Magenes
Giuliano Ramella
Mario Ungari
Marco Pandolfi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of DE60107074D1 publication Critical patent/DE60107074D1/de
Application granted granted Critical
Publication of DE60107074T2 publication Critical patent/DE60107074T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60107074T 2000-03-24 2001-03-19 Kristallin form ii von cabergolin Expired - Fee Related DE60107074T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0007307.2A GB0007307D0 (en) 2000-03-24 2000-03-24 Crystalline form || of cabergoline
GB0007307 2000-03-24
PCT/EP2001/003098 WO2001072747A1 (en) 2000-03-24 2001-03-19 Crystalline form ii of cabergoline

Publications (2)

Publication Number Publication Date
DE60107074D1 DE60107074D1 (de) 2004-12-16
DE60107074T2 true DE60107074T2 (de) 2005-10-20

Family

ID=9888432

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60107074T Expired - Fee Related DE60107074T2 (de) 2000-03-24 2001-03-19 Kristallin form ii von cabergolin

Country Status (31)

Country Link
US (2) US6673806B2 (sl)
EP (1) EP1280803B1 (sl)
JP (1) JP2003528874A (sl)
KR (1) KR20020081492A (sl)
CN (1) CN1221550C (sl)
AR (1) AR048279A1 (sl)
AT (1) ATE282038T1 (sl)
AU (1) AU783064B2 (sl)
BR (1) BR0109508A (sl)
CA (1) CA2399540A1 (sl)
CZ (1) CZ20023177A3 (sl)
DE (1) DE60107074T2 (sl)
DK (1) DK1280803T3 (sl)
EA (1) EA004376B1 (sl)
EE (1) EE200200544A (sl)
ES (1) ES2231461T3 (sl)
GB (1) GB0007307D0 (sl)
HK (1) HK1052692B (sl)
HU (1) HUP0300389A3 (sl)
IL (1) IL151670A0 (sl)
MX (1) MXPA02009284A (sl)
MY (1) MY126071A (sl)
NO (1) NO20024527L (sl)
NZ (1) NZ521314A (sl)
PE (1) PE20011087A1 (sl)
PL (1) PL358252A1 (sl)
PT (1) PT1280803E (sl)
SI (1) SI1280803T1 (sl)
SK (1) SK13572002A3 (sl)
WO (1) WO2001072747A1 (sl)
ZA (1) ZA200207151B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
JP2005529856A (ja) * 2002-03-15 2005-10-06 ファルマシア・コーポレーション カベルゴリンの結晶性ｉ型の製造方法
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
US7531551B2 (en) 2003-05-08 2009-05-12 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1953157A1 (en) * 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US20130163062A1 (en) 2011-12-22 2013-06-27 Qualcomm Mems Technologies, Inc. Mechanical smart window with continuously tunable transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149067A (en) * 1874-03-31 Improvement in steam-engine valve-gears
US187013A (en) * 1877-02-06 Improvement in ovens for gas-stoves
US144516A (en) * 1873-11-11 Improvement in faucets
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
NO20024527D0 (no) 2002-09-20
BR0109508A (pt) 2002-12-17
NZ521314A (en) 2004-05-28
MY126071A (en) 2006-09-29
CZ20023177A3 (cs) 2003-03-12
KR20020081492A (ko) 2002-10-26
US6673806B2 (en) 2004-01-06
SK13572002A3 (sk) 2003-04-01
EP1280803B1 (en) 2004-11-10
ZA200207151B (en) 2003-09-05
IL151670A0 (en) 2003-04-10
HK1052692A1 (en) 2003-09-26
US20030187013A1 (en) 2003-10-02
JP2003528874A (ja) 2003-09-30
ES2231461T3 (es) 2005-05-16
DE60107074D1 (de) 2004-12-16
EP1280803A1 (en) 2003-02-05
DK1280803T3 (da) 2005-01-24
PT1280803E (pt) 2005-02-28
SI1280803T1 (sl) 2005-04-30
AU4248201A (en) 2001-10-08
AR048279A1 (es) 2006-04-19
US6800635B2 (en) 2004-10-05
NO20024527L (no) 2002-09-20
GB0007307D0 (en) 2000-05-17
HUP0300389A2 (hu) 2003-07-28
ATE282038T1 (de) 2004-11-15
HK1052692B (zh) 2006-03-03
CA2399540A1 (en) 2001-10-04
EA200201017A1 (ru) 2003-02-27
HUP0300389A3 (en) 2004-08-30
PL358252A1 (en) 2004-08-09
AU783064B2 (en) 2005-09-22
MXPA02009284A (es) 2003-03-12
PE20011087A1 (es) 2001-10-04
EE200200544A (et) 2004-04-15
CN1418213A (zh) 2003-05-14
US20040072855A1 (en) 2004-04-15
CN1221550C (zh) 2005-10-05
WO2001072747A1 (en) 2001-10-04
EA004376B1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
DE3784478T2 (de) Benzopyran-verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
DE60107074T2 (de) Kristallin form ii von cabergolin
DE60100858T2 (de) Prozess zur herstellung der kristallinen form i von cabergolin
DE3685604T2 (de) 1,7-naphthyridinderivate und diese enthaltende arzneimittel.
DE3888913T2 (de) Kristallines beta-Lactam-Hydrat.
DE3717080C2 (de) 1-(Hydroxystyryl)-5H-2,3-benzodiazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0001115A2 (de) 2-Bromergosin und seine Säureadditionssalze, Verfahren zu deren Herstellung sowie deren Verwendung als Heilmittel
DE69104083T2 (de) Neue Antiulcus-Substanz.
US20030144516A1 (en) Crystalline form VII of cabergoline
DE2624789C3 (sl)
DE10212564B4 (de) 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
DE3721223C2 (sl)
DE69015834T2 (de) 6-Chlor-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzodiazepin-carbamate als Pro-Arzneimittel.
DE2329745C2 (de) Arzneimittel gegen Viren der Picorna-Gruppe
DE2113866A1 (de) Neue Indolderivate,Verfahren zu deren Herstellung und eine,diese Verbindungen enthaltende therapeutische Zusammensetzung
DE3634942A1 (de) Neue 4-benzyl-1-(2h)-phthalazinon-derivate
DE68902627T2 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
DE2755122C2 (de) Neue Acylderivate des Hellebrigenins, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
EP0665014A1 (de) 3-Benzoyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen mit anti-arrhythmischer Wirkung
DE60104822T2 (de) Pseudopolymorph von (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-on hydrochlorid
DE2607570A1 (de) Triazolobenzocycloalkylthiadiazin- derivate, verfahren zu ihrer herstellung und dieselben enthaltende pharmazeutische praeparate
DE2817558C2 (de) Antitumormittel mit einem Gehalt an Derivaten von Trans-4-(aminomethyl)cyclohexan-1-carbonsäure
AT380232B (de) Verfahren zur herstellung von neuen s(-)-3-(3-acetyl-4-(3-tert. butylamino-2hydroxypropoxy)-phenyl)-1,1-diaethylharnstoff und dessen pharmazeutisch vertraeglichen saeureadditionssalzen
DE68907893T2 (de) Neue 1,3,4,-thiadiazolderivate und antigeschwulstmittel, die diese enthalten.
DE1543838C (de) Basisch substituierte 1,3-Dioxolan-5-on- bzw. l,3-Oxathiolan-5-on-Derivate und Verfahren zu deren Herstellung und diese enthaltende Spasmolytica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee